Gut-brain Axis, Brain Function, and Behaviour.
Does Stimulating Friendly Gut Bacteria Improve Brain Function and Behaviour?
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Gershon Spitz, PhD
- Phone Number: +44 (0)1865611456
- Email: gershon.spitz@ndcn.ox.ac.uk
Study Locations
-
-
Oxfordshire
-
Oxford, Oxfordshire, United Kingdom, OX3 9DU
- Recruiting
- University of Oxford
-
Contact:
- University o Oxford
- Phone Number: 07438239953
- Email: gershon.spitz@ndcn.ox.ac.uk
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Trait anxiety levels > 40 on STAI trait inventory
- Participant is willing and able to give informed consent for participation in the study
- Not currently taking any psychoactive medications
Exclusion Criteria:
- Pregnant participants
- No contraindications to prebiotic administration
- Antibiotic, probiotics and/or prebiotic treatment in at least the two previous months.
- Participants who are taking any other food supplements that, in the opinion of the Investigators, may affect the results.
- Participants who are taking any medications that, in the opinion of the Investigators, may affect the results.
- Any significant change in diet which, at the discretion of the Investigators, may affect the results.
- Participants who have recently participated in another research trial which, at the discretion of the Investigators, may affect the results.
- A history of dementia, traumatic brain injury or stroke.
- Anyone who is unable to perform the behavioural tasks.
- Current use of any psychoactive medication.
- Current use of psychological treatment.
- Anyone who does not have adequate understanding of English, sufficient to give informed consent.
- Any person who has a history of drug abuse or a previous history of a neurological, or has a history of neurosurgical procedure is excluded as they may be at increased risk of epilepsy and data collected may be influenced by their condition.
- Anyone with any metal implants or implantable device would be excluded from any brain imaging studies as indicated by the MRI safety screening form.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Start with prebiotics
Half of the participants start with prebiotics, followed by a testing period.
After a wash-out period they will continue with placebo followed by a testing period.
|
Galactooligosaccharides (GOS) (prebiotics) will be consumed by the participants for 4-6 weeks
|
|
EXPERIMENTAL: Start with placebo
Half of the participants start with placebo, followed by a testing period.
After a wash-out period they will continue with prebiotics followed by a testing period.
|
Maltodextrin (placebo) will be consumed by the participants for 4-6 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cortisol awakening response (CAR)
Time Frame: Cortisol awakening responses will be measured at the end of the first intervention phase (4-6 weeks after study entry) and at the end of the second intervention phase (11-15 weeks post study entry).
|
CAR, a marker of stress responsivity, should be decreased after taking prebiotics compared to placebo (as previously found in non-anxious participants in Schmidt et al., 2015, Psychopharmacology)
|
Cortisol awakening responses will be measured at the end of the first intervention phase (4-6 weeks after study entry) and at the end of the second intervention phase (11-15 weeks post study entry).
|
|
Brain imaging (BOLD fMRI activity) in amygdala and cortical regions
Time Frame: Brain imaging will be measured at the end of the first intervention phase (4-6 weeks after study entry) and at the end of the second intervention phase (11-15 weeks post study entry).
|
Brain imaging (BOLD fMRI activity) in amygdala and cortical regions Will provide neural measures of threat reactivity.
We predict decreased amygdala and/or increased parietal-prefrontal brain activity after prebiotics compared to placebo, indicating an anxiolytic-like profile (fearful -neutral face trials in the low load condition) (as in Bishop et al, 2007 and Ironside et al, 2017)
|
Brain imaging will be measured at the end of the first intervention phase (4-6 weeks after study entry) and at the end of the second intervention phase (11-15 weeks post study entry).
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in gut microbiome
Time Frame: Changes in the microbiome will be measure using a single stool/faecal sample at four time points: baseline (0 weeks), following first intervention (4-6 weeks), following washout (7-9 weeks), and following the second intervention (11-15 weeks).
|
Availability of specific bacteria in microbiome will change as function of prebiotics and not during placebo.
The change will be measured at the start of each intervention compared to the end of each intervention
|
Changes in the microbiome will be measure using a single stool/faecal sample at four time points: baseline (0 weeks), following first intervention (4-6 weeks), following washout (7-9 weeks), and following the second intervention (11-15 weeks).
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
General Publications
- Schmidt K, Cowen PJ, Harmer CJ, Tzortzis G, Errington S, Burnet PW. Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy volunteers. Psychopharmacology (Berl). 2015 May;232(10):1793-801. doi: 10.1007/s00213-014-3810-0. Epub 2014 Dec 3.
- Bishop SJ, Jenkins R, Lawrence AD. Neural processing of fearful faces: effects of anxiety are gated by perceptual capacity limitations. Cereb Cortex. 2007 Jul;17(7):1595-603. doi: 10.1093/cercor/bhl070. Epub 2006 Sep 6.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- R52324_RE001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.